Hengyu Zhou1,2, Ying Cai1,3, Dina Liu1, Menghui Li1,4, Yu Sha1, Wenlu Zhang1, Kai Wang5, Jianping Gong4, Ni Tang1, Ailong Huang1,6, Jie Xia1. 1. Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Department of Infectious Diseases, The Second Affiliated Hospital, Institute for Viral Hepatitis, Chongqing Medical University, Chongqing, China. 2. Department of Intensive Care Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. 3. Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, Hangzhou, China. 4. Department of Liver, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China. 5. Department of Pathogenic Biology, College of Basic Medical Sciences, Chongqing Medical University, Chongqing, China. 6. College of Nursing, Chongqing Medical University, Chongqing, China.
Abstract
OBJECTIVES: Histone deacetylases (HDACs) are commonly dysregulated in cancer and represent promising therapeutic targets. However, global HDAC inhibitors have shown limited efficacy in the treatment of solid tumours, including hepatocellular carcinoma (HCC). In this study, we investigated the therapeutic effect of selectively inhibiting HDAC1 and 2 in HCC. METHODS: HDAC1 inhibitor Tacedinaline (CI994), HDAC2 inhibitor Santacruzamate A (CAY10683), HDAC1/2 common inhibitor Romidepsin (FK228) and global HDAC inhibitor Vorinostat (SAHA) were used to treat HCC cells. Cell cycle, apoptosis and the protein levels of CDKs and CDKNs were performed to evaluate HCC cell growth. Inhibition of HDAC1/2 by RNAi was further investigated. RESULTS: Combined inhibition of HDAC1/2 led to HCC cell morphology changes, growth inhibition, cell cycle blockage and apoptosis in vitro and suppressed the growth of subcutaneous HCC xenograft tumours in vivo. p21Waf1/Cip1 and p19INK4d , which play roles in cell cycle blockage and apoptosis induction, were upregulated. Inhibition of HDAC1/2 by siRNA further demonstrated that HDAC1 and 2 cooperate in blocking the cell cycle and inducing apoptosis via p19INK4d and p21Waf1/Cip1 upregulation. Finally, H3K18, H3K56 and H4K12 in the p19INK4d and p21Waf1/Cip1 promoter regions were found to be targets of HDAC1/2. CONCLUSIONS: Pharmacological or transcriptional inhibition of HDAC1/2 increases p19INK4d and p21Waf1/Cip1 expression, decreases CDK expression and arrests HCC growth. These results indicated a potential pharmacological mechanism of selective HDAC1/2 inhibitors in HCC therapy.
OBJECTIVES: Histone deacetylases (HDACs) are commonly dysregulated in cancer and represent promising therapeutic targets. However, global HDAC inhibitors have shown limited efficacy in the treatment of solid tumours, including hepatocellular carcinoma (HCC). In this study, we investigated the therapeutic effect of selectively inhibiting HDAC1 and 2 in HCC. METHODS:HDAC1 inhibitor Tacedinaline (CI994), HDAC2 inhibitor Santacruzamate A (CAY10683), HDAC1/2 common inhibitor Romidepsin (FK228) and global HDAC inhibitor Vorinostat (SAHA) were used to treat HCC cells. Cell cycle, apoptosis and the protein levels of CDKs and CDKNs were performed to evaluate HCC cell growth. Inhibition of HDAC1/2 by RNAi was further investigated. RESULTS: Combined inhibition of HDAC1/2 led to HCC cell morphology changes, growth inhibition, cell cycle blockage and apoptosis in vitro and suppressed the growth of subcutaneous HCC xenograft tumours in vivo. p21Waf1/Cip1 and p19INK4d , which play roles in cell cycle blockage and apoptosis induction, were upregulated. Inhibition of HDAC1/2 by siRNA further demonstrated that HDAC1 and 2 cooperate in blocking the cell cycle and inducing apoptosis via p19INK4d and p21Waf1/Cip1 upregulation. Finally, H3K18, H3K56 and H4K12 in the p19INK4d and p21Waf1/Cip1 promoter regions were found to be targets of HDAC1/2. CONCLUSIONS: Pharmacological or transcriptional inhibition of HDAC1/2 increases p19INK4d and p21Waf1/Cip1 expression, decreases CDK expression and arrests HCC growth. These results indicated a potential pharmacological mechanism of selective HDAC1/2 inhibitors in HCC therapy.
Authors: Benjamin E L Lauffer; Robert Mintzer; Rina Fong; Susmith Mukund; Christine Tam; Inna Zilberleyb; Birgit Flicke; Allegra Ritscher; Grazyna Fedorowicz; Roxanne Vallero; Daniel F Ortwine; Janet Gunzner; Zora Modrusan; Lars Neumann; Christopher M Koth; Patrick J Lupardus; Joshua S Kaminker; Christopher E Heise; Pascal Steiner Journal: J Biol Chem Date: 2013-07-29 Impact factor: 5.157
Authors: Karl Quint; Abbas Agaimy; Pietro Di Fazio; Roberta Montalbano; Claudia Steindorf; Rudolf Jung; Claus Hellerbrand; Arndt Hartmann; Helmut Sitter; Daniel Neureiter; Matthias Ocker Journal: Virchows Arch Date: 2011-06-29 Impact factor: 4.064
Authors: Kyle M Miller; Jorrit V Tjeertes; Julia Coates; Gaëlle Legube; Sophie E Polo; Sébastien Britton; Stephen P Jackson Journal: Nat Struct Mol Biol Date: 2010-08-29 Impact factor: 15.369
Authors: Talon J Aitken; Jacqueline E Crabtree; Daelin M Jensen; Kavan H Hess; Brennan R Leininger; Jeffery S Tessem Journal: Biol Cell Date: 2021-09-27 Impact factor: 4.458
Authors: Saira Justin; Jochen Rutz; Sebastian Maxeiner; Felix K-H Chun; Eva Juengel; Roman A Blaheta Journal: Int J Mol Sci Date: 2020-06-04 Impact factor: 5.923